- Prasad S Adusumilli
-
Memorial Sloan Kettering Cancer Center, New York
USA
- EWS14 "Novel concept and novel strategies of immunotherapy"
- EIS8 "Efforts to improve surgical outcomes 1"
- David Paul Carbone
-
The Ohio State University Comprehensive Cancer Center
USA
- ES4 "Progress in biology in lung cancer research"
- BEncore Session "CheckMate 017/057 5-year survival outcomes： NIVO vs Docetaxel in Previously Treated Advanced NSCLC"
- ES5 "Prospects for Cure in the I-O era"
- David R. Gandara
-
UC Davis Comprehensive Cancer Center
USA
- BS2 "How to apply NGS panel tests in daily practice"
- EWS14 "Novel concept and novel strategies of immunotherapy"
- LS16 "Latest Treatment Strategy for Lung Cancer"
- Marina Chiara Garassino
-
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Italy
- ES12 "Novel biomarkers for immunotherapies"
- EIS13 "Immunotherapy"
- LS1 "The latest treatment strategy for metastatic NSCLC"
- Fred R. Hirsch
-
Mount Sinai Cancer, Mount Sinai Health System The Icahn School of Medicine Tisch Cancer Institute
USA
- BS13 "Future of pathological diagnosis of lung cancers"
- ES3 "Predictive Biomarkers for Immunotherapy in Lung Cancer"
- Adi Gazdar Memorial Symposium
- Pasi A. Janne
-
Dana-Farber Cancer Institute
USA
- BS8 "New treatment options for EGFR mutated NSCLCs"
- EPresidential Symposium
- Franca Melfi
-
University hospital of Pisa, Pisa University
Italy
- BWS6 "Future perspectives of minimally invasive surgery"
- Tony Mok
-
The Chinese University of Hong Kong
China
- ES1 "First-line treatment strategies for NSCLCs without driver mutation"
- Sai-Hong Ignatius Ou
-
Chao Family Comprehensive Cancer Center
University of California Irvine School of MedicineUSA
- ES10 "ALK-TKIs Up-to-date"
- LS12 "What is the Optimal Treatment Algorism for ALK positive Lung Cancer?"
- Keunchil Park
-
Samsung Medical Center,
Sungkyunkwan University School of MedicineKorea
- ES11 "Novel drivers and novel agents in NSCLCs"
- EIS16 "Novel therapeutic approach"
- LS17 "How to make the best use of EGFR TKIs for patients with EGFR+ NSCLC"
- Solange Peters
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Oncology Department, LausanneSwizerland
- EWS14 "Novel concept and novel strategies of immunotherapy"
- LS11 "IO in stage Ⅲ NSCLC: Clinical Experience and Expectations for the future"
- Martin Reck
-
LungenClinic, Airway Research Center North, German Center of Lung Research
Germany
- ES1 "First-line treatment strategies for NSCLCs without driver mutation"
- LS10 "The optimal use for Immune checkpoint inhibitor in 1L treatment"
- Thanyanan Reungwetwattana
-
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hos;pital, Mahidol University
Thailand
- ES11 "Novel drivers and novel agents in NSCLCs"
- Charles Rudin
-
Memorial Sloan Kettering Cancer Center
USA
- EPresidential Symposium
- ES5 "SCLC Up-to-date
- Giorgio V. Scagliotti
-
University of Torino
Italy
- ES5 "SCLC Up-to-date"
- Johan F Vansteenkiste
-
Respiratory Oncology Unit, University Hospital KU Leuven
Belgium
- ES12 "Novel biomarkers for immunotherapies"
- ES4 "Strategies to improve overall survival in front line EGFRm NSCLC"
- Heather Wakelee
-
Medicine (Oncology) at the Stanford University Medical Center
USA
- ES1 "First-line treatment strategies for NSCLCs without driver mutation"
- BWS13 "Recent research & therapeutic topics in thymoma and thymic cancer"
- EIS4 "EGFR mutated lung cancer"
- LS7 "Clinical trial update on EGFR/ALK + NSCLC"
- EIASLC Session "JLCS and IASLC: Strengthening our Partnership"
- Yi-Long Wu
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences
China
- BS9 "Clinical stage III NSCLCs: current evidence and future direction"
- James Chih-Hsin Yang
-
National Taiwan University Hospital
Taiwan
- ES11 "Novel drivers and novel agents in NSCLCs"
- Caicun Zhou
-
Shanghai Pulmonary Hospital, Tongji University
China
- ES10 "ALK-TKIs Up-to-date"
